학술논문
In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteralesand Pseudomonas aeruginosafrom sub-Saharan Africa: ATLAS Global Surveillance Program 2017–2021
Document Type
Article
Author
Source
Journal of Global Antimicrobial Resistance; December 2023, Vol. 35 Issue: 1 p93-100, 8p
Subject
Language
ISSN
22137165
Abstract
•96.2% of all Enterobacterales isolates were ceftazidime-avibactam-susceptible.•Most ceftazidime-avibactam-resistant Enterobacterales isolates carried MBL genes.•88.9% of all Pseudomonas aeruginosaisolates were ceftazidime-avibactam-susceptible.•43.1% of ceftazidime-avibactam-resistant P. aeruginosaisolates carried MBL genes.•4.4% of Enterobacterales and 8.9% of P. aeruginosaisolates had a DTR phenotype.